4//SEC Filing
Burkly Linda 4
Accession 0001650664-24-000017
CIK 0001650664other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 8:03 PM ET
Size
9.1 KB
Accession
0001650664-24-000017
Insider Transaction Report
Form 4
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Transactions
- Award
Common Stock
2024-03-02+24,800→ 69,967 total - Award
Common Stock
2024-03-02+15,055→ 85,022 total - Award
Stock Option (right to buy)
2024-03-02+74,400→ 74,400 totalExercise: $10.53Exp: 2034-03-01→ Common Stock (74,400 underlying)
Footnotes (3)
- [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028.
- [F2]Reflects the acquisition, upon the achievement of a specified business development milestone, of a portion of a performance-based restricted stock unit award originally granted on July 24, 2023. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on July 24, 2024, subject to continued service.
- [F3]This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028.
Documents
Issuer
Editas Medicine, Inc.
CIK 0001650664
Entity typeother
Related Parties
1- filerCIK 0001985604
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 8:03 PM ET
- Size
- 9.1 KB